Ranbaxy and Merck Pen R&D Deal; Ranbaxy Could See Six-Year Earnings Surge With Recent Collaborations
This article was originally published in PharmAsia News
You may also be interested in...
"We Want To Shape Up Medical Treatment Paradigm Through Partnerships," Says Merck Asia-Pac President Ramesh Subrahmanian: An Interview With PharmAsia News (Part 1 of 2)
Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.
"We Want To Shape Up Medical Treatment Paradigm Through Partnerships," Says Merck Asia-Pac President Ramesh Subrahmanian: An Interview With PharmAsia News (Part 1 of 2)
Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.
Orchid To Develop Merck’s Anti-Coagulant; To Buy Majority Stake In Diakron
MUMBAI - Chennai-based injectible cephalosporin manufacturer Orchid Chemicals will develop and manufacture an oral anti-coagulant drug that was initially discovered by U.S. drug maker Merck